Haemonetics Corporation 10-Q Summary
Business Context and Reporting Period
Company: Haemonetics Corporation
Filing Type: Form 10-Q (Unaudited)
Period Ended: December 30, 2006 (Third Quarter of Fiscal Year 2007)
Business Overview: Haemonetics designs, manufactures, and markets automated systems for the collection, processing, and surgical salvage of donor and patient blood, along with related single-use disposables and information services. The company operates in one segment with product lines serving blood donors (Plasma, Blood Bank, Red Cell) and patients (Surgical, OrthoPAT).
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Dec 30, 2006 |
Three Months Ended Dec 31, 2005 |
Nine Months Ended Dec 30, 2006 |
Nine Months Ended Dec 31, 2005 |
|---|---|---|---|---|
| Net Revenues | $113,527 | $105,677 | $332,688 | $309,338 |
| Gross Profit | $56,419 | $55,669 | $168,953 | $161,958 |
| Gross Margin % | 49.7% | 52.7% | 50.8% | 52.4% |
| Operating Income | $17,005 | $41,141 | $37,052 | $74,653 |
| Net Income | $16,902 | $27,924 | $29,324 | $51,391 |
| Diluted EPS | $0.62 | $1.01 | $1.06 | $1.87 |
| Cash & Equivalents | $227,707 (as of Dec 30, 2006) | |||
| Total Debt | $30,076 (Current: $23,248; Long-term: $6,828) | |||
| Working Capital | $313,264 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 7.4% for the quarter and 7.5% year-to-date (YTD), driven primarily by growth in U.S. Plasma and Red Cell disposable sales and price improvements in the OrthoPAT line. This was partially offset by lower volumes in Japan and unfavorable foreign exchange impacts.
- Profitability Decline: Operating income decreased 58.7% for the quarter and 50.4% YTD. This decline is largely non-recurring, attributed to the absence of a $26.4 million arbitration award income recorded in the prior year's third quarter.
- Expense Increases: Operating expenses rose significantly due to:
- Acquisition Costs: A $9.1 million charge for In-Process Research and Development (IPR&D) related to the acquisition of Arryx, Inc.
- Stock Compensation: Adoption of SFAS 123R resulted in approximately $7.4 million in stock-based compensation expense for the nine-month period.
- Restructuring: $2.9 million in pre-tax restructuring costs related to international sales reorganization.
- Excluding One-Time Items: Management notes that excluding the arbitration award, IPR&D charge, stock compensation, and restructuring costs, operating income actually increased 29.7% for the quarter and 16.1% YTD.
Guidance, Outlook, and Risks
- Acquisitions:
- Arryx, Inc.: Acquired on July 18, 2006, for approximately $26 million in cash plus existing investments. The acquisition added holographic optical trapping technology.
- IDM Acquisition: Subsequent to the period end (Jan 30, 2007), the company acquired Information Data Management, Inc. for approximately $9 million.
- Legal Settlements:
- Baxter Arbitration: A $30.8 million award received in late 2005 boosted prior-year results. A subsequent settlement of $6 million regarding platelet pathogen reduction contracts was reached in January 2007, expected to add $0.12 to Q4 2007 EPS.
- Share Repurchases: The company completed a $40.0 million share repurchase program in November 2006, purchasing approximately 0.9 million shares.
- Foreign Exchange Risk: Approximately 57% of sales are generated outside the U.S. (primarily Japan and Europe). A strengthening U.S. dollar negatively impacts reported results. The company uses forward contracts to hedge anticipated cash flows.
- Outlook: Management expects the annual tax rate to be approximately 35.0% for the remainder of fiscal year 2007. No specific revenue guidance was provided in this filing.
Investor Verification Checklist
- Non-Recurring Items: Verify the impact of the $26.4 million prior-year arbitration award and the $9.1 million current-year IPR&D charge when assessing core operating performance.
- Foreign Exchange Sensitivity: Monitor the U.S. Dollar vs. Japanese Yen and Euro exchange rates, as currency fluctuations significantly impact gross profit and operating income.
- Japan Market Performance: Review trends in the Japanese market, where Blood Bank and Plasma volumes have declined due to competitive rebalancing and a shift to whole blood-derived plasma.
- Stock-Based Compensation: Assess the ongoing impact of SFAS 123R adoption on future operating margins.
- Subsequent Events: Confirm the integration and financial impact of the January 2007 IDM acquisition and the $6 million Baxter settlement.